Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Decrease in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 240,400 shares, a decline of 37.8% from the November 30th total of 386,500 shares. Approximately 3.1% of the company’s stock are short sold. Based on an average daily volume of 3,380,000 shares, the days-to-cover ratio is presently 0.1 days.

Virpax Pharmaceuticals Stock Up 20.6 %

VRPX stock traded up $0.07 during midday trading on Friday, hitting $0.41. The company’s stock had a trading volume of 4,074,046 shares, compared to its average volume of 2,458,838. The stock’s 50-day moving average price is $0.52 and its 200 day moving average price is $0.74. Virpax Pharmaceuticals has a 1 year low of $0.29 and a 1 year high of $5.48.

Wall Street Analyst Weigh In

Separately, Maxim Group reiterated a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, October 9th.

Hedge Funds Weigh In On Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 32.23% of the company’s stock.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.